10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $1.78 billion. The enterprise value is $1.42 billion.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 124.49 million shares outstanding. The number of shares has increased by 2.95% in one year.
| Current Share Class | 114.41M |
| Shares Outstanding | 124.49M |
| Shares Change (YoY) | +2.95% |
| Shares Change (QoQ) | +1.55% |
| Owned by Insiders (%) | 8.17% |
| Owned by Institutions (%) | 96.39% |
| Float | 112.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.71 |
| Forward PS | 2.93 |
| PB Ratio | 2.30 |
| P/TBV Ratio | 2.36 |
| P/FCF Ratio | 31.30 |
| P/OCF Ratio | 26.59 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 24.96 |
Financial Position
The company has a current ratio of 5.84, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.84 |
| Quick Ratio | 5.05 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.53 |
| Interest Coverage | -28,881.00 |
Financial Efficiency
Return on equity (ROE) is -11.30% and return on invested capital (ROIC) is -10.79%.
| Return on Equity (ROE) | -11.30% |
| Return on Assets (ROA) | -9.45% |
| Return on Invested Capital (ROIC) | -10.79% |
| Return on Capital Employed (ROCE) | -16.64% |
| Revenue Per Employee | $493,466 |
| Profits Per Employee | -$64,779 |
| Employee Count | 1,306 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.50 |
Taxes
In the past 12 months, 10x Genomics has paid $5.27 million in taxes.
| Income Tax | 5.27M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.85% in the last 52 weeks. The beta is 2.03, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | -37.85% |
| 50-Day Moving Average | 12.54 |
| 200-Day Moving Average | 12.08 |
| Relative Strength Index (RSI) | 62.35 |
| Average Volume (20 Days) | 3,405,932 |
Short Selling Information
The latest short interest is 14.46 million, so 11.61% of the outstanding shares have been sold short.
| Short Interest | 14.46M |
| Short Previous Month | 14.26M |
| Short % of Shares Out | 11.61% |
| Short % of Float | 12.86% |
| Short Ratio (days to cover) | 4.59 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $644.47 million and -$84.60 million in losses. Loss per share was -$0.69.
| Revenue | 644.47M |
| Gross Profit | 448.28M |
| Operating Income | -144.41M |
| Pretax Income | -233.22M |
| Net Income | -84.60M |
| EBITDA | -110.85M |
| EBIT | -144.41M |
| Loss Per Share | -$0.69 |
Full Income StatementBalance Sheet
The company has $447.26 million in cash and $86.74 million in debt, giving a net cash position of $360.52 million or $2.90 per share.
| Cash & Cash Equivalents | 447.26M |
| Total Debt | 86.74M |
| Net Cash | 360.52M |
| Net Cash Per Share | $2.90 |
| Equity (Book Value) | 773.28M |
| Book Value Per Share | 6.21 |
| Working Capital | 543.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $66.95 million and capital expenditures -$10.08 million, giving a free cash flow of $56.88 million.
| Operating Cash Flow | 66.95M |
| Capital Expenditures | -10.08M |
| Free Cash Flow | 56.88M |
| FCF Per Share | $0.46 |
Full Cash Flow StatementMargins
Gross margin is 69.56%, with operating and profit margins of -22.41% and -13.13%.
| Gross Margin | 69.56% |
| Operating Margin | -22.41% |
| Pretax Margin | -12.31% |
| Profit Margin | -13.13% |
| EBITDA Margin | -17.20% |
| EBIT Margin | -22.41% |
| FCF Margin | 8.83% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.95% |
| Shareholder Yield | -2.95% |
| Earnings Yield | -4.75% |
| FCF Yield | 3.19% |
Dividend DetailsAnalyst Forecast
The average price target for 10x Genomics is $13.41, which is -6.22% lower than the current price. The consensus rating is "Buy".
| Price Target | $13.41 |
| Price Target Difference | -6.22% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 3.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 3.88 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.88 |
| Piotroski F-Score | 5 |
